Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Meldola

443 clinical trials in Meldola, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Meldola at a glance
443
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

443 trials in Meldola

Open in trial search

Pancreatic carcinoma metastatic

Recruiting

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel

Small cell lung cancer

Recruiting

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC

Non-small cell lung cancer

Recruiting

A study to evaluate the safety and effectiveness of HLX43 in patients with advanced non-small cell lung cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:HLX43
  • Sponsor:Shanghai Henlius Biotech Inc.

Colorectal cancer metastatic

Recruiting

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Small cell lung cancer+2

Recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

Pancreatic neuroendocrine tumour

Recruiting

A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Exelixis Inc.

Cachexia

Recruiting

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Visugromab
  • Sponsor:CatalYm GmbH

Colorectal cancer metastatic

Recruiting

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Squamous cell carcinoma of lung+6

Recruiting

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE

Neoplasm malignant

Recruiting

Study on Long-term Safety of Nivolumab and Drug Combination for Cancer Patients from Previous BMS Trials

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Acute myeloid leukaemia

Recruiting

Study on RVU120 and Venetoclax for Patients with Acute Myeloid Leukemia After Previous Treatment Failure

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Ryvu Therapeutics S.A.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Meldola

What the registry says about research in the country

01 Hematologic Malignancies

Innovative research focusing on blood cancers, including studies of novel therapeutic combinations for acute myeloid leukemia, multiple myeloma, and various lymphomas.

  • Advanced treatments for diffuse large B-cell lymphoma
  • Multiple myeloma therapies for transplant-ineligible patients
  • Novel approaches in myelodysplastic syndrome

Studies are evaluating targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Solid Tumors

Comprehensive research into advanced solid tumors, with particular emphasis on colorectal cancer, non-small cell lung cancer, and breast cancer.

  • Targeted therapies for metastatic colorectal cancer
  • Novel combinations for advanced NSCLC
  • Innovative approaches in metastatic breast cancer

Investigations focus on personalized treatment strategies and novel drug combinations.

03 Genitourinary Cancers

Groundbreaking studies in urological cancers, including research on prostate cancer, urothelial cancer, and renal cell carcinoma.

  • Advanced treatments for metastatic prostate cancer
  • Maintenance therapy in urothelial cancer
  • Immunotherapy approaches in renal cell carcinoma

Research aims to improve survival rates through innovative therapeutic strategies.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.